ArticleAMB Express2025
Propeptide-mediated enhancement of hyperthermophilic subtilisin-like protease expression in Escherichia coli.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extreme thermal environments: reservoirs of industrially important thermozymes.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Subtilisin-like serine proteases (subtilases) are widely used in industrial applications, particularly in the detergents, due to their robust catalytic properties. The hyperthermophilic archaeon Thermococcus kodakarensis KOD1 secretes TKSP, a highly stable subtilase capable of degrading pathogenic prion proteins under harsh conditions. TKSP is secreted as a precursor comprising an N-terminal propeptide (TKSPpro) fused to the catalytic domain. Although the TKSP precursor can be solubly expressed in Escherichia coli, TKSPpro, which transiently inhibits the catalytic domain, is rapidly cleaved. This releases active TKSP prematurely, leading to degradation of host proteins and severely limiting production yields. To address this issue, we developed a co-expression system in which the TKSP precursor is expressed alongside TKSpro, the propeptide of TKS, a homologous subtilase from T. kodakarensis KOD1. TKSpro is a potent inhibitor of its cognate catalytic domain due to its high structural rigidity and strong binding affinity. Co-expression with TKSpro enhanced TKSP expression levels by up to tenfold compared to expression without the propeptide. Crystallographic analysis of TKSpro in complex with TKSP lacking TKSPpro revealed that TKSpro binds complementarily to the catalytic domain, with the extended C-terminal region occupying the substrate-binding pocket. Mutational analysis further demonstrated that the structural rigidity and inhibitory potency of TKSpro correlates with TKSP expression yield in the co-expression system. This study demonstrates the importance of forming a stable inhibitory complex with an exogenous propeptide to suppress premature activation and enhance heterologous expression of cytotoxic subtilases in E. coli, providing a useful strategy for the production of proteolytically active enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.